



## **First Echopulse® Commercial Agreement with a Private Imaging Center Expands Treatment in France**

### **New Business Development Director Joins Theraclion for Northern Europe**

**Paris, FRANCE – December 15, 2014 – THERACLION** (Alternext, FR0010120402 – ALTHE), a company specializing in cutting-edge medical equipment for echotherapy, today announced the order of its Echopulse system by the private imaging center SELAS du Nedon in Istres for the treatment of breast fibroadenomas and thyroid nodules.

This marks the first commercial agreement with a private imaging center. The SELAS du Nedon group plans to use the Echopulse device at its sites in Istres, expanding treatment access to patients living in the south of France.

*“There is a growing demand amongst patients for non-invasive treatment alternatives,”* says Dr. Jean-Marc Treutenaere. *“The Echopulse device allows us to treat these benign lesions in an outpatient setting without scarring and under simple local anesthesia. This is an important improvement in patient care, particularly for the younger patient population that is more often affected by breast fibroadenomas.”*

*“The commercial agreement with the Echopulse system at the imaging center of Istres is another significant step in our company’s growth and the expanded adoption of echotherapy,”* says David Caumartin, CEO of Theraclion. *“We remain focused on pioneering the therapeutic use of ultrasound in breast fibroadenomas and thyroid nodules and expanding patient access to its benefits.”*

In France, in addition to this new center, the Echopulse system is currently being used by the American Hospital of Paris and the Diaconesses Croix Saint-Simon hospital in Paris. Worldwide, 10 systems are in use. Theraclion is currently the only company in the world offering a completely non-invasive treatment for breast fibroadenomas and benign thyroid nodules.

Theraclion also announced the appointment of Michael Leach as Vice-President UK & Northern Europe. *“Michael is a charismatic entrepreneur who will drive echotherapy adoption by leveraging our clinical studies and in particular the one done at Guy’s & St. Thomas”*, says David Caumartin. Leach started his career as a lead radiographer in the NHS and then quickly evolved in various business development positions inside General Electric and Nuffield Health Group. He successfully developed managed services and healthcare provider businesses in the UK.

**About Theraclion**

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on cutting-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.

Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 23 people, 65 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion's website: [www.theraclion.com](http://www.theraclion.com).

**Theraclion is listed on Alternext Paris**

**Eligible for the PEA-PME, a tax-exempt share savings plan for SMEs**

**Ticker symbol: ALTHE – ISIN code: FR0010120402**

**Contacts:****Theraclion**

David Caumartin

CEO

Phone: +33 (0)1 55 48 90 70

[david.caumartin@theraclion.com](mailto:david.caumartin@theraclion.com)

**NewCap**

Financial Communications & Investor Relations

Emmanuel Huynh / Sophie Boulila

Phone: +33 (0)1 44 71 94 91

[theraclion@newcap.fr](mailto:theraclion@newcap.fr)

**ALIZE RP**

Press relations

Caroline Carmagnol / Valentine Boivin

Phone: + 33 (0)1 44 54 36 63

[theraclion@alizerp.com](mailto:theraclion@alizerp.com)

